Earnings
Lilly's $20 Billion Bet: Why the World's Hottest Drug Company Is Reinventing Itself as a Vaccine Giant
There is a phrase that gets used a lot in pharmaceutical strategy circles: "diversification beyond the blockbuster." The idea is simple. A drug company that depends on one or two mega-products for the bulk of its revenue is one patent cliff away from a crisis. Eli Lilly